Amplification of HER-2/neu and Topoisomerase IIα in Primary and Metastatic Breast Cancer
作者： Jorma Isola , Minna Tanner , Päivi Järvinen
DOI:
关键词:
摘要: Amplification of the HER-2/neu oncogene and amplification topoisomerase IIα gene are important determinators response to chemotherapy in advanced breast cancer. Assays these genes usually carried out using primary tumor samples, because biopsies from metastatic lesions not taken. We studied concordance Her-2/neu tumors their metastases by immunostaining DNA situ hybridization. amplification, present 28% ( n = 46), was always associated with its metastasis. Conversely, no were seen without tumor. Topoisomerase II α copy status (amplification/deletion/unaltered) remained generally unchanged -positive tumors, but three cases, predominant cell population tissue only as a subpopulation conclude that measured reflects metastases. Minor discrepancies between may reflect evolvement amplicon structure successive divisions.
aacrjournals.org参考文章(11)
J A Fletcher, J S Ross, HER-2/neu (c-erb-B2) gene and protein in breast cancer. American Journal of Clinical Pathology. ,vol. 112, ,(1999)
Karin Rennstam, Jorma Isola, Bo Baldetorp, Minna Tanner, Soili Kytölä, Chromosomal Rearrangements and Oncogene Amplification Precede Aneuploidization in the Genetic Evolution of Breast Cancer Cancer Research. ,vol. 61, pp. 1214- 1219 ,(2001)
Yosef Yarden, Mark X. Sliwkowski, Untangling the ErbB signalling network Nature Reviews Molecular Cell Biology. ,vol. 2, pp. 127- 137 ,(2001) , 10.1038/35052073
Tero A.H. Järvinen, Minna Tanner, Virpi Rantanen, Maarit Bärlund, Åke Borg, Seija Grénman, Jorma Isola, Amplification and deletion of topoisomerase IIα associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer American Journal of Pathology. ,vol. 156, pp. 839- 847 ,(2000) , 10.1016/S0002-9440(10)64952-8
Tero A.H. J�rvinen, Minna Tanner, Maarit B�rlund, �ke Borg, Jorma Isola, Characterization of topoisomerase II? gene amplification and deletion in breast cancer Genes, Chromosomes and Cancer. ,vol. 26, pp. 142- 150 ,(1999) , 10.1002/(SICI)1098-2264(199910)26:2<142::AID-GCC6>3.0.CO;2-B
Jahn M. Nesland, Lars Ottestad, Anne-Lise Børresen, Kåre E. Tvedt, Ruth Holm, Reino Heikkilä, Kjell Tveit, The c-erbB-2 Protein in Primary and Metastatic Breast Carcinomas Ultrastructural Pathology. ,vol. 15, pp. 281- 289 ,(1991) , 10.3109/01913129109021890
Minna Tanner, David Gancberg, Angelo Di Leo, Denis Larsimont, Ghizlane Rouas, Martine J. Piccart, Jorma Isola, Chromogenic in Situ Hybridization: A Practical Alternative for Fluorescence in Situ Hybridization to Detect HER-2/neu Oncogene Amplification in Archival Breast Cancer Samples American Journal of Pathology. ,vol. 157, pp. 1467- 1472 ,(2000) , 10.1016/S0002-9440(10)64785-2
Gudrun Huper, Matthias H. Kraus, J. Dirk Iglehart, Jeffrey R. Marks, Billie Jo Kerns, Beatrice C. Langton, Increased erbB-2 gene copies and expression in multiple stages of breast cancer Cancer Research. ,vol. 50, pp. 6701- 6707 ,(1990)
Günter Schlimok, Isabella Heumos, Gert Riethmüller, Stephan Braun, Klaus Pantel, Lutz Riethdorf, Gerhard Schaller, erbB2 Overexpression on Occult Metastatic Cells in Bone Marrow Predicts Poor Clinical Outcome of Stage I–III Breast Cancer Patients Cancer Research. ,vol. 61, pp. 1890- 1895 ,(2001)
Dennis J. Slamon, Brian Leyland-Jones, Steven Shak, Hank Fuchs, Virginia Paton, Alex Bajamonde, Thomas Fleming, Wolfgang Eiermann, Janet Wolter, Mark Pegram, Jose Baselga, Larry Norton, Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2 The New England Journal of Medicine. ,vol. 344, pp. 783- 792 ,(2001) , 10.1056/NEJM200103153441101